Prioritization
FDA Launches Pilot Program to Prioritize U.S. Generic Drug Manufacturing and Testing
FDA; pilot program; generic drugs; ANDA prioritization; domestic manufacturing; bioequivalence testing; U.S. pharmaceutical supply chain; drug approval; supply chain resilience
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics Amid Cost-Cutting Measures
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, cost-cutting, strategic productivity initiative, portfolio prioritization
Repare Therapeutics Cuts 25% of Workforce, Preclinical Team Most Affected
Repare Therapeutics, layoffs, preclinical team, R&D prioritization, biotech industry
Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization
Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin